Celgene reaffirms 2020 financial outlook

Celgene noted it is advancing five late-stage assets with U.S. approvals expected through 2020; Ozanimod U.S. and EU regulatory submissions on-track for Q1 of 2019.
https://thefly.com/landingPageNews.php?id=2856721